Fig. 5: Neutralization assays with African green monkey (AGM) sera.
Neutralization assays using day 25 sera from MV-014-212-vaccinated AGMs (1) 09720, (2) C8959, and (3) C6672. a Pseudovirus neutralization assay (PNA) showing NT50 values and a convalescent sera control at 1859 IU/mL. The data shown is the average of two technical replicates, bars are geometric mean and error bars indicate geometric standard deviation. b Surrogate virus neutralization assay (sVNA) results using the USA-WA1/2020 strain RBD. The data shown is the average of two technical replicates, bars are mean and error bars indicate standard deviation. c Pre-immune and post-vaccination surrogate virus neutralization titers of individual AGMs. Each data point represents the mean of two technical replicates, except for post-vaccination D3356, D3254, D4339, and C8546. For these animals, only one technical replicate was tested due to insufficient sample volume. Error bars denote SD. d Plaque reduction neutralization assay (PRNA). Serum from the AGM O9720, showing the highest titers in (a) and (b) was used in a 50% plaque-reduction neutralization test performed in a biosafety level 3 facility. The neutralization titers of this AGM against wild-type SARS-CoV-2 or two variants of concern (Beta/B.1.351 and Alpha/B.1.1.7) are shown. The convalescent serum used in this assay is the same as in (a). The limit of detection is 20 and is indicated as a dashed line. e Surrogate virus neutralization results using the Delta/B.1.617.2 strain RBD or the USA-WA1/2020 (WA-1) RBD on serum from the AGM O9720. For (d) and (e), the data shown is the average of two technical replicates and bars indicate standard deviation. Statistical analysis was one-way ANOVA using Tukey’s multiple comparisons test. p-values are shown. LOD: limit of detection. LLOQ: lower limit of quantification.
